Table 1.
Clinical characteristics of patients with ankylosing spondylitis
| Variable | M0 | M3 | M12 | P value |
|---|---|---|---|---|
| Gender; Female/Male | 6/13 | - | - | NA |
| Age; years | 38.16 [15.22] | - | - | NA |
| HLA-B27 positivity; n (%) | 19 (100 %) | - | - | NA |
| CRP; mg/l | 22.61 [29.47] | 3.09 [8.01] | 3.96 [5.70] | <0.001a,b NSc |
| ESR; mm/h | 36 [26] | 6 [18] | 11 [23] | <0.001a,b NSc |
| BASDAI | 6.45 [3.05] | 2.40 [1.92] | 1.67 [1.40] | <0.001a,b NSc |
| ASDAS-CRP | 4.15 [0.93] | 2.28 [0.92] | 1.63 [0.84] | <0.001a,b NSc |
| Anti-TNF therapy; n (%) | ||||
| Adalimumab | 3 (16 %) | - | - | NA |
| Infliximab | 6 (32 %) | - | - | NA |
| Golimumab | 5 (26 %) | - | - | NA |
| Etanercept | 5 (26 %) | - | - | NA |
| AS stage; n (%) | ||||
| Stage I | 3 (16 %) | - | - | NA |
| Stage II | 2 (10 %) | - | - | NA |
| Stage III | 4 (21 %) | - | - | NA |
| Stage IV | 9 (48 %) | - | - | NA |
| Stage V | 1 (5 %) | - | - | NA |
Abbreviations: AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity index; CRP, C-reactive protein; ESR, Erythrocyte Sedimentation Rate; NA, not applicable; NS, not significant; Data are presented as a median and interquartile range [IQR].
a
, comparison between M0 and M3;
b
, comparison between M0 and M12;
c
, comparison between M3 and M12.